Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota

Abstract

Hyperuricemic nephropathy (HN) is a common clinical complication of hyperuricemia. The pathogenesis of HN is directly related to urea metabolism in the gut microbiota. Febuxostat, a potent xanthine oxidase inhibitor, is the first-line drug used for the treatment of hyperuricemia. However, there have been few studies on the pharmacokinetics of febuxostat in HN animal models or in patients. In this study, a high-purine diet-induced HN rat model was established. The pharmacokinetics of febuxostat in HN rats was evaluated using LC-MS/MS. Astragaloside IV (AST) was used to correct the abnormal pharmacokinetics of febuxostat. Gut microbiota diversity analysis was used to evaluate the effect of AST on gut microbiota. The results showed that the delayed elimination of febuxostat caused drug accumulation after multiple administrations. Oral but not i. p. AST improved the pharmacokinetics of febuxostat in HN rats. The mechanistic study showed that AST could regulate urea metabolism in faeces and attenuate urea-ammonia liver-intestine circulation. Urease-related genera, including Eubacterium, Parabacteroides, Ruminococcus, and Clostridia, decreased after AST prevention. In addition, the decrease in pathogenic genera and increase in short-chain fatty acids (SCFA) producing genera also contribute to renal function recovery. In summary, AST improved the pharmacokinetics of febuxostat in HN rats by comprehensive regulation of the gut microbiota, including urea metabolism, anti-calcification, and short-chain fatty acid generation. These results imply that febuxostat might accumulate in HN patients, and AST could reverse the accumulation through gut microbiota regulation.

Effects of Astragaloside IV on Hearing, Inflammatory Factors, and Intestinal Flora in Mice Exposed to Noise

“…However, AS-IV decreased the protein levels of TNF-α and IL-6 in adipocytes through the miR-21/PTEN/PI3K/AKT signaling pathway [67]. Other studies have shown that AS-IV can interact with the gut microbiota and be decomposed and used by the gut microbiota, inducing the production of various beneficial short-chain fatty acids, which can reduce the degree of systemic inflammation [39,68].…”

Si Miao San relieves hyperuricemia by regulating intestinal flora

“…Parabacteroides is also a urease-related genus, and its elevation is involved in hyperuricemia-related renal injury (Zhao et al, 2022). Zhao et al (2022) reported that the abundance of Parabacteroides increases in rats with hyperuricemic nephropathy. In addition, Corynebacterium is a group of Gram-positive bacteria and is frequently categorized as opportunistic pathogens (Luo et al, 2022).…”

“…P. johnsonii is implicated in the regulation of host immunity (Cui et al, 2022). Parabacteroides is also a urease‐related genus, and its elevation is involved in hyperuricemia‐related renal injury (Zhao et al, 2022). Zhao et al (2022) reported that the abundance of Parabacteroides increases in rats with hyperuricemic nephropathy.…”

Visualization of renal rotenone accumulation after oral administration and in situ detection of kidney injury biomarkers via MALDI mass spectrometry imaging

“…The renal organ assumes a crucial function in the processes of drug metabolism and elimination, rendering its susceptibility to the adverse effects of drug-induced toxicity ( Bajaj et al, 2018 ). The LC-MS/MS study conducted by Zhao et al (2022) demonstrated that febuxostat, a drug used to treat hyperuricemia, exhibited renal accumulation in rats with significant renal impairment following repeated administrations. Their findings revealed a plausible detrimental impact on individuals with pre-existing renal impairment.…”